Cargando…

Immunotherapeutics /

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Donev, Rossen (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Cambridge, MA : Academic Press, 2022.
Colección:Advances in protein chemistry and structural biology ; 129
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000Ii 4500
001 SCIDIR_on1305066150
003 OCoLC
005 20231120010637.0
006 m o d
007 cr cnu---unuuu
008 220323s2022 mau o 000 0 eng d
040 |a OPELS  |b eng  |e rda  |e pn  |c OPELS  |d OCLCO  |d EBLCP  |d OCLCF  |d YDX  |d UKMGB  |d SFB  |d UKAHL  |d OCLCQ 
015 |a GBC208694  |2 bnb 
016 7 |a 020452291  |2 Uk 
019 |a 1304815609  |a 1305011403  |a 1305166106  |a 1351993670 
020 |z 9780323992275 
020 |a 9780323992282  |q (electronic bk.) 
020 |a 0323992285  |q (electronic bk.) 
020 |z 0323992277 
035 |a (OCoLC)1305066150  |z (OCoLC)1304815609  |z (OCoLC)1305011403  |z (OCoLC)1305166106  |z (OCoLC)1351993670 
050 4 |a RM275 
082 0 4 |a 616.079  |2 23 
245 0 0 |a Immunotherapeutics /  |c Edited by Rossen Donev. 
264 1 |a Cambridge, MA :  |b Academic Press,  |c 2022. 
300 |a 1 online resource (1 volume) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 0 |a Advances in protein chemistry and structural biology ;  |v 129 
588 0 |a Print version record. 
505 0 |a Intro -- Immunotherapeutics -- Copyright -- Contents -- Contributors -- Chapter One: In silico tools and databases for designing cancer immunotherapy -- 1. Introduction -- 2. Cancer associated genomic data -- 2.1. Genome profile repositories -- 2.2. Mutation profile databases -- 2.3. Cancer biomarker repositories -- 3. Immunological database -- 4. Analysis of genomic profiles -- 5. Prediction of cancer biomarkers -- 6. Identification of vaccine candidates -- 6.1. B-cell epitope -- 6.2. MHC binders -- 6.3. T-cell epitope -- 6.4. Cytokines inducing peptides -- 6.5. Neoepitope for cancer 
505 8 |a 7. Important pipelines -- 7.1. HLA typing -- 7.2. Neoantigen -- 8. Cancer-specific immunotherapy -- 9. Miscellaneous -- 10. Discussion and conclusion -- Acknowledgments -- References -- Chapter Two: Immunotherapeutic approaches for HPV-caused cervical cancer -- 1. Introduction -- 2. HPV -- 2.1. Structure -- 2.2. HPV types -- 2.3. Viral life cycle and pathogenesis -- 2.4. Immune response to HPV infection -- 3. Vaccines -- 4. HPV therapeutic vaccines -- 4.1. Peptide-/protein-based vaccines -- 4.2. Vector-based vaccines -- 4.3. Nano-delivery systems -- 4.4. DNA-based vaccines 
505 8 |a 4.5. RNA-based vaccines -- 4.6. Cell-based vaccines -- 4.6.1. Dendritic cell-based vaccines -- 4.6.2. Tumor-cell-based vaccines -- 4.6.3. Adoptive T-cell therapy -- 4.7. Therapeutic HPV vaccines in combination with therapeutic modalities -- 4.7.1. Therapeutic HPV vaccines accompanied by immune checkpoint blockade -- 4.7.2. Therapeutic HPV vaccines along with chemo-immunotherapy and radiotherapy -- 4.7.3. Therapeutic HPV vaccines in combination with other treatment modalities -- 5. Conclusion -- Funding -- Conflicts of interest -- References 
505 8 |a Chapter Three: Natural killer cell-based strategies for immunotherapy of cancer -- 1. Natural killer cells origin and functions -- 2. NK cell recognition in health and disease -- 2.1. NK cell receptor families -- 2.1.1. C-type lectin-like receptors -- 2.1.2. Killer immunoglobulin-like receptors -- 2.1.3. Natural cytotoxicity receptors -- 3. NK cells as a tool of cancer immunotherapy -- 3.1. Cancer immunosurveillance -- 3.2. Mechanisms of tumor escape from NK cell immunosurveillance -- 4. NK cell-based immunotherapeutics -- 4.1. Activated NK cell-based therapeutics 
505 8 |a 4.2. Recombinant protein-based NK cell therapeutics -- 4.3. Gene-modified NK cell-based therapeutics -- 5. Concluding remarks -- Acknowledgments -- References -- Chapter Four: Noncoding RNAs as novel immunotherapeutic tools against cancer -- 1. Introduction -- 2. Immunotherapy in human diseases -- 3. Immunotherapy in cancer -- 4. Noncoding RNAs in cancer -- 4.1. Reprogramming of macrophage differentiation & function by ncRNAs -- 4.2. Modulation of natural killer cell mediated cytotoxicity by ncRNAs -- 4.3. Regulation of neutrophil plasticity & activity by ncRNAs 
650 0 |a Immunotherapy. 
650 2 |a Immunotherapy  |0 (DNLM)D007167 
650 6 |a Immunoth�erapie.  |0 (CaQQLa)201-0067406 
650 7 |a Immunotherapy.  |2 fast  |0 (OCoLC)fst00968044 
700 1 |a Donev, Rossen,  |e editor. 
776 0 8 |i Print version:  |t IMMUNOTHERAPEUTICS.  |d [Place of publication not identified] : ELSEVIER ACADEMIC PRESS, 2022  |z 0323992277  |w (OCoLC)1264711987 
856 4 0 |u https://sciencedirect.uam.elogim.com/science/bookseries/18761623/129  |z Texto completo